[ET Net News Agency, 22 October 2021] Kintor Pharmaceutical Limited (09939) said the
clinical trial of dual-targeting antibody (GT90008) for the treatment of advanced solid
tumours was approved by the National Medical Products Administration (NMPA) of China on 21
October 2021.
GT90008 is the company's second novel antibody drug that has entered clinical stage.
(RC)